Evidence map›Paper›PMID 35223675›Full record

ArticleClinical and experimental vaccine research2022

Alopecia areata after COVID-19 vaccination.

Giuseppe Gallo, Luca Mastorino, Luca Tonella, Simone Ribero, Pietro Quaglino

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Clinical and experimental vaccine research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Alopecia areata following COVID-19 vaccine: a systematic review.European journal of medical research · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Alopecia Areata after COVID-19 Vaccines.Skin appendage disorders · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Giuseppe GalloDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-8390-4467
Luca MastorinoDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-7386-3219
Luca TonellaDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-6790-554X
Simone RiberoDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-0098-1406
Pietro QuaglinoDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0003-4185-9586
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) vaccines are authorized for use in numerous countries worldwide. Several cutaneous findings are reported after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a patient with a rapid onset of alopecia areata immediately after receiving the second dose of the COVID-19 vaccine. Alopecia areata is a common autoimmune disease leading to non-scarring hair loss. Among the many cutaneous adverse effects reported after the anti-SARS-COV2 vaccination, no episodes of alopecia areata have been described to date. In this paper, we report the first case of alopecia areata after COVID-19 vaccination described in the literature with a revision of cases of alopecia areata reported after other types of vaccination. Although the significance of these skin reactions is not yet known, further studies will certainly clarify whether the development of alopecia areata or other forms of immune-mediated reactions could represent a positive prognostic factor regarding immune protection from SARS-CoV-2.

Indexed as

Alopecia areataCOVID-19TrichoscopyVaccine

Identifiers

PMID35223675
PMCPMC8844677
OpenAlexW4213255243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.